Get the Stockscreener App
1.50
0.00%
0.00
After Hours:
1.49
-0.01
-0.67%
Cytosorbents Corp stock is traded at $1.50, with a volume of 70,902.
It is up +0.00% in the last 24 hours and up +42.86% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$1.50
Open:
$1.59
24h Volume:
70,902
Relative Volume:
0.68
Market Cap:
$81.64M
Revenue:
$31.09M
Net Income/Loss:
$-28.51M
P/E Ratio:
-2.50
EPS:
-0.6
Net Cash Flow:
$-22.59M
1W Performance:
-1.32%
1M Performance:
+42.86%
6M Performance:
+57.89%
1Y Performance:
-20.21%
1-Day Range:
$1.43
$1.59
1-Week Range:
$1.26
$1.59
52-Week Range:
$0.70
$2.15
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com - Defense World
Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com - MarketBeat
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - MarketBeat
Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com - Defense World
Stocks of Cytosorbents Corp (CTSO) are poised to climb above their peers - SETE News
Technical analysis of Cytosorbents Corp (CTSO) stock chart patterns - US Post News
Cytosorbents (NASDAQ:CTSO) Share Price Passes Above Two Hundred Day Moving Average of $0.94 - MarketBeat
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference - Yahoo Finance
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference - StockTitan
Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com - MarketBeat
Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com - Defense World
CytoSorbents amends royalty agreement with ROKK LLC - Investing.com
CytoSorbents (STU:HQE1) Earnings Yield % : N/A% (As of Aug. 20, 2024) - GuruFocus.com
B. Riley Analysts Cut Earnings Estimates for Cytosorbents Co. (NASDAQ:CTSO) - MarketBeat
CTSO (CytoSorbents) Inventory-to-Revenue : 0.46 (As of Jun. 2024) - GuruFocus.com
CTSO (CytoSorbents) 3-Year EPS without NRI Growth Rate : -38.10% (As of Jun. 2024) - GuruFocus.com
HC Wainwright Reaffirms “Neutral” Rating for Cytosorbents (NASDAQ:CTSO) - Defense World
Cytosorbents Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits - Quantisnow
Cytosorbents Co. (NASDAQ:CTSO) Forecasted to Post Q3 2024 Earnings of ($0.05) Per Share - Defense World
Cytosorbents Co. (NASDAQ:CTSO) Forecasted to Post Q3 2024 Earnings of ($0.05) Per Share - MarketBeat
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Analysts Offer Predictions for Cytosorbents Co.'s Q1 2025 Earnings (NASDAQ:CTSO) - MarketBeat
Cytosorbents Co. to Post Q1 2025 Earnings of ($0.02) Per Share, HC Wainwright Forecasts (NASDAQ:CTSO) - Defense World
Cytosorbents (NASDAQ:CTSO) Announces Earnings Results, Beats Estimates By $0.01 EPS - Defense World
Cytosorbents Corporation (NASDAQ:CTSO) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: CytoSorbents sees growth and prepares for FDA submission - Investing.com
CytoSorbents: Q2 Earnings Snapshot - San Antonio Express-News
CytoSorbents names Peter Mariani as new CFO - Investing.com
CytoSorbents: Q2 Earnings Snapshot - Darien Times
StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
CytoSorbents: Q2 Earnings Snapshot - The Washington Post
CytoSorbents: Q2 Earnings Snapshot - The Advocate
CytoSorbents: Q2 Earnings Snapshot - Barchart
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results - Quantisnow
Cytosorbents (CTSO) to Release Quarterly Earnings on Tuesday - MarketBeat
Cytosorbents (CTSO) Set to Announce Earnings on Tuesday - Defense World
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results - Yahoo Finance
Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com - MarketBeat
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement - StockTitan
CytoSorbents unveils newly redesigned, unified company and product website - ROI-NJ.com
Cytosorbents (NASDAQ:CTSO) Upgraded to "Strong-Buy" by EF Hutton Acquisition Co. I - MarketBeat
Cytosorbents (NASDAQ:CTSO) Upgraded by EF Hutton Acquisition Co. I to “Strong-Buy” - Defense World
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website - ForexTV.com
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website - Yahoo Finance
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - Defense World
CytoSorbents to Present at the Inaugural American - GlobeNewswire
Cytosorbents (NASDAQ:CTSO) Stock Passes Above Two Hundred Day Moving Average of $0.93 - Defense World
Cytosorbents (NASDAQ:CTSO) Stock Passes Above 200 Day Moving Average of $0.93 - MarketBeat
StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO) - MarketBeat
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):